Successful management of postoperative recurrence of hepatocellular carcinoma with p53 gene therapy combining transcatheter arterial chemoembolization

Yong-Song Guan, Yuan Liu, Long Sun, Xiao Li, Qing He

Abstract
Transcatheter arterial chemoembolization (TACE) has become the standard treatment for unresectable hepatocellular carcinoma (HCC). But this method has some shortages. p53 gene, which was found to be mutant in many human tumors, has been proved with broad-spectrum anti-tumor effects. We reported a 23-year-old patient with recurrent HCC after irregular hepatectomy. The p53 gene was applied to this patient. We injected percutaneously and infused transcatheterally p53 gene (Gendicine, Shenzhen Sibiono Bentech, China) into his recurrent nodules in liver respectively and 4 d later, the patient received TACE therapy. In the 2 mo follow-up, the patient was in good clinical condition with normal liver function and no recurrence was identified. The case report proposed that recurrent HCC could be successfully treated with p53 gene therapy combining TACE.

CASE REPORT
A 23-year old man with HCC in right lobe was treated with right lobe irregular hepatectomy 20 mo ago. Five months after the procedure, several recurrent nodules were found in the remnant liver in a routine post-operation CT scan. This patient did not have any clinical symptom. Afterward, the patient received traditional Chinese medicine therapy, but no effect was found. And some clinical manifestations of liver function impairment such as belly swollen, lose of appetite and jaundice occurred gradually with AFP (alpha-fetoprotein)>1 210 ng/mL. Three months ago, the patient presented at the hospital. In the light of the multiple hepatic nodules (Figure 1), which were not indicated for re-operation, we were determined to treat this patient with p53 gene therapy combining TACE. Firstly, we punctured the largest nodule with fine needle percutaneously under the guidance of CT and after the tip of needle was confirmed within the largest nodule, p53 (Gendicine, Shenzhen Sibiono Bentech, China) was injected into intra-tumor in a fashion of multiple injections. Then, we infused p53 through hepatic artery transcatheterally in our catheter room. A total of $3 \times 10^{12}$ VP (virus particles) were administered. After the procedure, the patient had a moderate fever ranging 38-38.5 °C and no complication was observed. Four days later, we super-selectively embolized the patient’s hepatic arteries with 5-Fu, vidroelbione, iodized oil. After the uneventful post-operative 30 d, the CT examination of the abdomen was made and the image demonstrated the complete deposit of oil and no recurrence sign was identified (Figure 2). In the following 2 mo (until this paper was written), the patient was in good clinical condition with normal liver function and no recurrence was identified.

DISCUSSION
Hepatocellular carcinoma (HCC) is a highly malignant tumor with a very high morbidity and mortality. It has a poor prognosis due to its rapid infiltrating growth and complicating
liver cirrhosis. Since TACE was introduced as a palliative treatment in patients with unresectable HCC, it has become one of the most common forms of interventional therapy. However, its therapeutic effect is also limited by the lack of appropriate and reliable embolic agents and when the tumor is infiltrative in nature or is hypovascular, too large or too small. Another limitation of TACE is the need for repeated treatments, which can result in deterioration of liver function. The combination of limited TACE with PEI or RFA, irradiation therapy may lead to improved survival and decreased risk of liver failure. In this case, we adopted the combined therapy of p53 with TACE so as to overcome the downside of TACE.

p53 tumor suppressor gene is praised as gene guardian and the loss of p53 is thought to be responsible for the lack of apoptotic signals in tumor cells and thus for their uncontrolled proliferation and recurrence. Many human tumors carry mutations in the p53 and mutant or absent p53 status has been associated with resistance to radiation therapy and to apoptosis-inducing chemotherapy. The combination of p53 gene transduction with radiation or chemotherapy has resulted in local tumor control that is superior to either therapy alone. In HCC, the incidence of p53 mutation was reported as 61% (17/28). Chen et al. also reported that mutations in the p53 gene were frequently detected in recurrent HCC and the interval between surgical resection and the recurrence of HCC was significantly longer in patients with the wild-type p53 gene than those with mutations, strongly suggesting a pathological role for the mutant p53 gene in HCC. Jeng et al. maintained that the biological behavior of the mutant p53 gene is strongly related to the invasiveness of HCC and may also influence the postoperative course. Many scholars suggest that the immunopositivity of the mutant p53 gene has a predictive role in the prognosis of patients with resected hepatocellular carcinoma.

Gendicine, recombinant human ad-p53 injection, (Shenzhen Sibiono Bentech, China) obtained a drug license from the state food and drug administration of China (SFDA; Beijing, China) and became the world’s first commercially-licensed gene therapy drug. Gendicine consists of advenovirus vectors and normal p53 tumor suppressor gene. Gendicine was used in clinical trials on patients with late-stage HNSCC (head and neck squamous cell carcinoma). After 8 wk of therapy involving one injection per week, 64% of patients’ tumors experienced complete regression and 32% experienced partial regression. In combination with chemo- and radiotherapy, it improved treatment efficacy more than three-fold.

Although the recommended indications are limited in HNSCC according to its specification, in this case, Gendicine was tried in the patient with recurrent HCC. Because of the multiple tumor nodules in liver parenchyma, this patient was not suitable for re-operation. So we tried the new gene drug. Three hours after the intra-tumor injection and transcatheter hepatic artery infusion with a total of 3×10^12 VP (virus particles), Gendicine began to express P53 protein in tumor cell and reached a peak at post injection d 3. The P53 protein brings about specific anti-tumor cells effect in such ways as induction of apoptosis or necrosis, incentive of body immune response, regulation of cell cycle etc. We treated the patient with TACE at post injection d 4 in expectation of achieving an optimal therapeutic effect. Thirty days later, we used CT to evaluate the therapeutic effect. The CT scan images identified complete iodized oil uptake in tumor areas. HCC images that revealed a dense enhancement on contrast enchanced CT had a significantly retention of lipiodol within the whole tumor or revealed no uptake in tumor areas. HCC images that revealed a dense enhancement on contrast enchanced CT had a significantly retention of lipiodol within the whole tumor or revealed no uptake in tumor areas.

REFERENCES

1. Chen XM, Luo PF, Lin HH, Zhou ZJ, Shao PJ, Fu L, Li WK. Long-term result of combination of transcatheter arterial chemoembolization and percutaneous ethanol injection for treatment of hepatocellular carcinoma. Aichest 2004; 23: 829-832

2. Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J, Ayuso C, Sala M, Muchart J, Sola R, Rodes J, Bruix J. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma:
a randomised controlled trial. **Lancet** 2002; **359**: 1734-1739

3 **Mizoe A, Yamaguchi J, Azuma T, Fujitaka H, Furuji J, Kanematsu T.** Transcatheter arterial embolization for advanced hepatocellular carcinoma resulting in a curative resection: report of two cases. **Hepatogastroenterology** 2000; **47**: 1706-1710

4 **Llovet JM, Bruix J.** Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. **Hepatology** 2003; **37**: 429-442

5 **Lin DY, Lin SM, Liaw YF.** Non-surgical treatment of hepatocellular carcinoma. **J Gastroenterol Hepatol** 1997; **12**: S319-S328

6 **Ahrar K, Gupta S.** Hepatic artery embolization for hepatocellular carcinoma: technique, patient selection, and outcomes. **Surg Oncol Clin N Am** 2003; **12**: 105-126

7 **Kouraklis G.** Progress in cancer gene therapy. **Acta Oncol** 1999; **38**: 673-683

8 **Friedmann T.** Gene therapy of cancer through restoration of tumor-suppressor functions? **Cancer** 1992; **70**: 1810-1817

9 **Hsia CC, Nakashima Y, Thorgerirsson SS, Harris CC, Minemura M, Momosaki S, Wang NJ, Tabor E.** Correlation of immunohistochemical staining and mutations of p53 in human hepatocellular carcinoma. **Oncol Rep** 2000; **7**: 353-356

10 **Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, Housman DE, Jacks T.** p53 status and the efficacy of cancer therapy **in vivo**. **Science** 1994; **266**: 807-810

11 **Gjerset RA, Turla ST, Sobol RE, Scalise JJ, Mercola D, Collins H, Hopkins PJ.** Use of wild-type p53 to achieve complete treatment sensitization of tumor cells expressing endogenous mutant p53. **Mol Carcinog** 1995; **14**: 275-285

12 **Nguyen DM, Spitz FR, Yen N, Cristiano RJ, Roth JA.** Gene therapy for lung cancer: enhancement of tumor suppression by a combination of sequential systemic cisplatin and adenovirus-mediated p53 gene transfer. **J Thorac Cardiovasc Surg** 1996; **112**: 1372-1376; discussion 1376-1377

13 **Chen GG, Merchant JL, Lai PB, Ho RL, Hu X, Okada M, Huang SF, Chui AK, Law DJ, Li YG, Lau WY, Li AK.** Mutation of p53 in recurrent hepatocellular carcinoma and its association with the expression of ZBP-89. **Am J Pathol** 2003; **162**: 1823-1829

14 **Jeng KS, Sheen IS, Chen BF, Wu JY.** Is the p53 gene mutation of prognostic value in hepatocellular carcinoma after resection? **Arch Surg** 2000; **135**: 1329-1333

**Science Editor Li WZ  Language Editor Elsevier HK**